Wegovy and Ozempic are the same active drug — semaglutide — from the same maker, but they are approved and labeled for different uses and reach different maximum doses. Here’s a neutral rundown of how they differ. This is educational, not medical advice; which one is right for you is a prescriber’s call.
| Ozempic | Wegovy | |
|---|---|---|
| Active drug | Semaglutide | Semaglutide |
| FDA-approved use | Type 2 diabetes (and CV risk reduction) | Chronic weight management |
| Standard max dose | 2 mg weekly | 2.4 mg weekly |
| Form | Multi-dose pen | Single-dose pens |
Because they’re approved for different conditions, coverage and cost can differ, and you can’t simply swap one for the other on your own — the dosing and pens aren’t interchangeable. A prescriber decides which product and dose fit your situation.
Insurance often treats a diabetes drug and a weight-management drug differently, which is why one may be covered and the other not. See ways people lower GLP-1 costs (informational, no vendor picks).
Yes — both are semaglutide from the same maker. They differ in FDA-approved use, maximum dose, and pen format.
On the standard schedules, Wegovy goes to 2.4 mg weekly and Ozempic to 2 mg weekly.
Not on your own — the products and pens are not interchangeable. Any switch is a decision for your prescriber.
Plans often cover a diabetes drug and a weight-management drug differently, so the same molecule can be covered under one label and not the other.
Both share semaglutide’s side-effect profile. Higher doses can mean more digestive effects for some people; experiences vary.